Mapi Pharma Ltd.
http://www.mapi-pharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Mapi Pharma Ltd.
Viatris And Mapi Knocked Back On Once-Monthly US Copaxone Rival
Viatris offered little in the way of detail as it announced a setback for its Mapi Pharma-partnered proposed once-monthly glatiramer acetate product for relapsing forms of multiple sclerosis. The firm has previously shouted from the rooftops about Mapi’s Phase III clinical study and the potential to establish a new standard of care for glatiramer acetate patients.
Mapi Hits Milestone For Viatris-Partnered Long-Acting Glatiramer
Fresh from a $20m investment from partner Viatris, Mapi Pharma has announced significant progress in its Phase III trial for a long-acting version of Copaxone, which is to be filed through the FDA’s 505(b)(2) hybrid pathway.
Deal Watch: GSK Invests In Early-Stage Synthetic Lethality Programs At Ideaya
Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.
Mylan Ups Investment In Mapi’s Monthly Glatiramer
Mylan has invested a further $20m in a monthly glatiramer acetate depot product being developed by partner Mapi for submission via the 505(b)(2) route in the US.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice